Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

Sameh Mosaad FoudaDepartment of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, EgyptCorrespondence[email protected]

Ahmed M BahgatDepartment of Ophthalmology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Pages 567-571 | Published online: 23 Mar 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

AbràmoffMDLouYErginayAImproved automated detection of diabetic retinopathy on a publicly available dataset through integration of deep learningInvest Ophthalmol Vis Sci2016575200520627701631
PubMed Web of Science ®Google Scholar
HolekampNMOverview of diabetic macular edemaAm J Manag Care201622284291
PubMedGoogle Scholar
DugelPUHillenkampJSivaprasadSBaseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trialsClin Ophthalmol2016101103111027366049
PubMedGoogle Scholar
ShahCPHeierJSAflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thicknessOphthalmic Surg Lasers Imaging Retina20164783683927631479
PubMed Web of Science ®Google Scholar
IshidaSUsuiTYamashiroKVEGF164 is proinflammatory in the diabetic retinaInvest Ophthalmol Vis Sci2003442155216212714656
PubMed Web of Science ®Google Scholar
RossELHuttonDWSteinJDBresslerNMJampolLMGlassmanARCost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trialJAMA Ophthalmol201613488889627280850
PubMed Web of Science ®Google Scholar
CălugăruDCălugăruMConversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edemaAm J Ophthalmol201616829029127270364
PubMed Web of Science ®Google Scholar
ShahSUHarlessABleauLMaturiRKProspective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edemaRetina2016361986199627124881
PubMed Web of Science ®Google Scholar
NguyenQDBrownDMMarcusDMRanibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDEOphthalmology201211978980122330964
PubMed Web of Science ®Google Scholar
NguyenQDShahSMKhwajaAATwo-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) studyOphthalmology20101172146215120855114
PubMed Web of Science ®Google Scholar
ScottIUEdwardsARBeckRWA phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edemaOphthalmology20071141860186717698196
PubMed Web of Science ®Google Scholar
KorobelnikJFDoDVSchmidt-ErfurthUIntravitreal aflibercept for diabetic macular edemaOphthalmology20141212247225425012934
PubMed Web of Science ®Google Scholar
MitchellPBandelloFSchmidtEUThe RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edemaOphthalmology201111861562521459215
PubMed Web of Science ®Google Scholar
IshibashiTLiXKohAThe REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edemaOphthalmology20151221402141525983216
PubMed Web of Science ®Google Scholar
WellsJAGlassmanARAyalaARAflibercept, bevacizumab, or ranibizumab for diabetic macular edemaN Engl J Med20151311931203
Google Scholar
DugelPUHillenkampJSivaprasadSBaseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trialsClin Ophthalmol2016101103111027366049
PubMedGoogle Scholar
WatanabeDSuzumaKSuzumaIVitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathyAm J Ophthalmol200513947648115767056
PubMed Web of Science ®Google Scholar
AdamisAPMillerJWBernalMTIncreased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathyAm J Ophthalmol199411844454507943121
PubMed Web of Science ®Google Scholar
BandelloFCicinelliMVParodiMBAnti-VEGF molecules for the management of diabetic macular edemaCurr Pharm Des2015214731473726350530
PubMed Web of Science ®Google Scholar
CalvoCMSridharJShahlaeeAHoACReduction of diabetic macular edema in the untreated fellow eye following intravitreal injection of afliberceptOphthalmic Surg Lasers Imaging Retina20164747447627183553
PubMed Web of Science ®Google Scholar
EganCZhuHLeeAThe United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedemaBr J Ophthalmol20171011758027965262
PubMed Web of Science ®Google Scholar
NguyenQDShahSMKhwajaAATwo-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) studyOphthalmology20101172146215120855114
PubMed Web of Science ®Google Scholar
HeierJSBresslerNMAveryRLComparison of aflibercept, bevacizumab and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practiceJAMA Ophthalmol201613495927466983
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date